A Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Advanced Solid Tumors and Metastatic Brain Cancer (ANG1005-CLN-02).

Trial Profile

A Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Advanced Solid Tumors and Metastatic Brain Cancer (ANG1005-CLN-02).

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Paclitaxel trevatide (Primary)
  • Indications Brain metastases; Solid tumours
  • Focus Adverse reactions
  • Sponsors AngioChem
  • Most Recent Events

    • 15 May 2014 According to the Angiochem media release, the clinical data from this trial presented at the American Society of Clinical Oncology (ASCO) 50th Annual meeting May 30-June 3, 2014 in Chicago, IL.
    • 09 Jun 2010 Changes: added actual pt number 56
    • 09 Jun 2010 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top